The 2024-2025 Evidence: Stimulants Work Differently Than We Thought
A landmark study published in Cell (December 2025) by Washington University researchers Kay and Dosenbach analyzed brain imaging data from 5,795 children in the ABCD Study and upended decades of assumptions about stimulant medications. The key finding: stimulants do not primarily act on attention networks at all. Instead, they work through arousal and reward pathways—essentially producing brain activity patterns nearly identical to getting adequate sleep.
Children taking stimulants showed brain connectivity indistinguishable from well-rested children, even when sleep-deprived. Lead author Benjamin Kay explained, “I’ve always been taught that they facilitate attention systems to give people more voluntary control over what they pay attention to. But we’ve shown that’s not the case. Rather, the improvement we observe in attention is a secondary effect of a child being more alert and finding a task more rewarding.”
This discovery has profound implications for understanding tolerance. The February 2024 JAMA Psychiatry dose-response meta-analysis (Farhat et al.) examined 47 randomized trials with 7,714 adult participants and found that for methylphenidate, benefits significantly diminish beyond a moderate daily dose, with half of the maximum effect reached at a relatively low dose. For amphetamines, the dose-response curve approaches a plateau—higher doses provide virtually no additional symptom reduction while doubling the risk of dropout from adverse effects. The clinical message: when medication seems less effective, dose escalation typically offers diminishing returns; addressing underlying causes or switching strategies works better.
The MTA study’s 16-year follow-up showed that 63.8% of participants experienced fluctuating periods of symptom remission and recurrence—suggesting that apparent medication “failure” often reflects the natural course of ADHD rather than true drug tolerance. Researchers noted that medications “may, at least in some cases, have an ‘expiration date’ with respect to effectiveness,” but distinguishing this from disease fluctuation or other confounding factors remains clinically challenging.
What Actually Happens in the Brain During Chronic Stimulant Treatment
Understanding the neurobiological mechanisms helps explain why euphoric effects fade while therapeutic benefits usually persist. Chronic stimulant treatment triggers several compensatory brain adaptations, most of which are homeostatic responses—the brain attempting to maintain equilibrium.
Dopamine transporter upregulation represents the primary tolerance mechanism. A PET imaging study (Wang et al., 2013) found that 12 months of methylphenidate treatment produced a 24% increase in striatal dopamine transporter (DAT) density compared to untreated controls. Animal studies show even larger increases (54-106% in various striatal regions), but critically, these changes are completely reversible after approximately one month of abstinence.
The dopamine receptor changes differ between receptor subtypes. D1 receptors, which are involved in working memory and cognitive function, undergo upregulation and recycle back to the cell surface after internalization. D2 receptors, which mediate reward and euphoria, are instead targeted for degradation through a protein called GASP-1. This differential receptor fate creates an altered D1:D2 ratio that may explain why cognitive benefits persist while euphoric effects diminish.
The critical insight lies in regional brain differences. Euphoria requires rapid, large dopamine increases in the nucleus accumbens (the brain’s reward center), while therapeutic effects on attention, working memory, and impulse control are mediated primarily by the prefrontal cortex. At clinically relevant doses, stimulants preferentially increase catecholamines in the prefrontal cortex while having substantially smaller effects on the nucleus accumbens—perhaps a 25-50% greater elevation in the PFC compared to reward circuits. This regional selectivity explains why the “high” fades while functional improvement remains: the reward circuit adapts more rapidly than the cognitive circuit.
When it’s Not Actually Tolerance: The Most Common Culprits
Before attributing reduced medication effectiveness to tolerance, clinicians should systematically rule out several common mimics that create the appearance of medication failure.
Sleep deprivation may be the most underappreciated factor. The Washington University study found that ADHD diagnosis was associated with 14.8 fewer minutes of sleep per night, and up to 85% of adults with ADHD have sleep disturbances (with a 5.18 odds ratio for insomnia compared to non-ADHD populations). Because stimulants work partly by producing “well-rested brain” activity patterns, their effectiveness depends on baseline sleep quality. Evaluation for sleep apnea, restless leg syndrome, and delayed sleep phase disorder should precede any assumption of medication tolerance.
Iron and ferritin deficiency directly impairs dopamine synthesis because iron serves as a cofactor for tyrosine hydroxylase, the rate-limiting enzyme in dopamine production. Meta-analysis of 10 studies (2,191 participants) found significantly lower serum ferritin in ADHD patients, with 84% of ADHD children having ferritin below 30 ng/mL in one study. Research shows a direct correlation: lower ferritin predicts higher required amphetamine doses (Spearman’s r = −0.45, p < 0.007). The clinical threshold of concern is ferritin below 30 ng/mL, though some experts suggest optimal cognitive function requires levels of 50-70 ng/mL.
Comorbid anxiety and depression affect up to 75% of adults and 80% of children with ADHD. Untreated anxiety can create a vicious cycle where ADHD symptoms worsen anxiety, and anxiety worsens the subjective experience of ADHD treatment. Similarly, depression’s anhedonia, fatigue, and cognitive symptoms overlap substantially with ADHD and can mask medication benefits. A longitudinal study found ADHD patients with comorbid major depression had 232% increased risk of treatment resistance.
Thyroid dysfunction shows a surprising overlap with ADHD symptoms — hyperthyroidism mimics hyperactive ADHD (restlessness, impulsivity), while hypothyroidism mimics inattentive ADHD (fatigue, poor concentration). Children with hyperthyroidism show 1.7 times higher ADHD prevalence. A full thyroid panel (TSH, free T3, free T4) should be standard before concluding that stimulants have stopped working.
Vitamin C and acidic substances reduce amphetamine absorption and increase renal excretion through pH effects. The FDA labeling for Adderall XR specifically warns that “gastrointestinal acidifying agents (ascorbic acid, fruit juices, etc.) lower absorption of amphetamines.” Patients should take stimulants at least one hour before or after citrus juices, vitamin C supplements, or acidic beverages — though notably, lisdexamfetamine (Vyvanse) is unaffected because it’s a prodrug with different absorption characteristics.
Hormonal fluctuations significantly impact stimulant response in women. Estrogen increases dopamine synthesis and reduces reuptake; during the luteal phase (when estrogen declines), women respond less strongly to psychostimulants and may report medication feeling less effective. Emerging research suggests cycle-adjusted dosing — increasing stimulant doses premenstrually — may improve symptom control, though only about seven studies have examined this systematically.
Evidence-Based Management Strategies When Medication Seems Inadequate
Clinical guidelines from CADDRA, AAP, and NICE provide a systematic approach when stimulant effectiveness appears to wane.
Formulation switching within the same medication class represents the first-line intervention. If symptoms improve but wear off too quickly, switching from immediate-release to extended-release formulations or prodrugs (lisdexamfetamine) often resolves the problem. In some cases, a prescriber may modestly increase a long-acting morning dose to extend how long it lasts. The key distinction: if the medication works initially but doesn’t last, change the delivery mechanism; if the medication doesn’t work at all, change the compound class.
Switching between stimulant classes (methylphenidate to amphetamine or vice versa) shows consistent clinical benefit. Research indicates that approximately 40% of patients respond to both medication classes, while another 40% respond preferentially to only one. A 2021 study found 41% of medication-naive adults required switching from their initial stimulant family within 90 days due to poor tolerability. CADDRA guidelines explicitly state: “Patients who do not respond to one stimulant may respond to another.” For suspected tolerance specifically, case reports suggest switching classes for approximately 10-30 days may “reset” tolerance mechanisms.
Medication holidays remain controversial but are practiced by 25-70% of families with children on stimulants. The strongest evidence supports longer breaks (summer holidays) for growth catch-up, with some case reports suggesting approximately one month of abstinence may reset tolerance—consistent with animal studies showing DAT upregulation reverses within this timeframe. NICE guidelines recommend annual medication reviews with consideration of structured treatment interruptions. However, holidays carry risks of symptom return, and non-stimulant medications (atomoxetine, guanfacine, clonidine) require continuous dosing and should never have drug holidays.
Non-stimulant alternatives provide options when stimulants prove inadequate or poorly tolerated. Atomoxetine (Strattera) achieves effect sizes of 0.57-0.7 compared to stimulants’ 0.95-1.0, with full effects emerging over 4-6 weeks; it may particularly benefit patients with comorbid anxiety. Viloxazine ER (Qelbree), approved in 2021, shows faster onset (1-2 weeks) and demonstrated significantly greater symptom reduction than atomoxetine in an open-label comparison study. Guanfacine XR (Intuniv) and clonidine XR (Kapvay) work as alpha-2 agonists, particularly effective for hyperactivity, impulsivity, emotional dysregulation, and comorbid tics. Combination therapy — adding guanfacine or clonidine to stimulants — has FDA approval for ages 6-17 and shows clinically superior results for residual hyperactivity/impulsivity after stimulant optimization. An open-label study of 75 patients adding guanfacine XR to suboptimal stimulant response showed significant additional symptom reduction, with ADHD rating scores decreasing to near-normal ranges.
The Crucial Distinction Patients Must Understand
The most important concept for patient education is the difference between euphoria fading (normal and expected) versus therapeutic tolerance (uncommon). This distinction prevents unnecessary dose escalation and medication changes.
When treatment begins, patients often experience what clinicians call the “honeymoon period”—an initial sense of clarity, energy, or relief that can feel almost euphoric. One patient education resource explains this through a helpful analogy: “Anyone who has gone through life with an unconscious 15-kilo rucksack will naturally feel ‘lighter’ in the first few days after putting it down. However, the aim of medication is not to preserve the positively perceived feeling of relief of these first few days, but only to eliminate the difficulty.”
The neurobiological explanation: at clinically appropriate doses, stimulants produce minimal effects on the nucleus accumbens (reward center) while substantially increasing dopamine and norepinephrine in the prefrontal cortex (cognitive center). Adults with ADHD report that the “reinforcing” effects of methylphenidate come from improvements in cognitive functioning—increased focus and concentration—rather than euphoria. This differs fundamentally from non-ADHD adults, who report effects related to “high” feelings.
Patients should track functional outcomes, not subjective feelings. Key metrics include:
- Task completion rates (finishing what you start)
- Time management (meeting deadlines, arriving on time)
- Organizational success (finding things, keeping appointments)
- Relationship quality (fewer conflicts, better communication)
- Work or school performance (objective measures like evaluations or grades)
The Weiss Functional Impairment Rating Scale (WFIRS) provides a standardized way to measure these real-world outcomes. As Dr. Margaret Weiss notes: “Patients care more about whether the presenting problem has improved than they care about whether symptoms improve.” The medication is working if life is functioning better—regardless of whether patients feel it the same way they initially did.
A red flag emerges when patients request higher doses because the medication doesn’t “feel like it used to,” without corresponding functional impairment. This pattern—focusing on subjective sensations rather than objective outcomes—can indicate dose-chasing behavior rather than true tolerance.
Safety considerations and recognizing problematic patterns
A 2025 meta-analysis in Frontiers in Psychiatry found that 22.6% of ADHD patients report past-year misuse of their prescribed stimulants, and 18.2% report diversion (giving away or selling medication). Risk factors include being prescribed amphetamine-based stimulants (versus methylphenidate), having comorbid depressive or anxiety symptoms, and believing that misuse carries no risk.
Clinical red flags for dose-chasing behavior include: frequent requests for dose increases without corresponding functional improvement, early refill requests or “lost prescription” claims, strong preference for immediate-release formulations, using medication for purposes unrelated to ADHD symptoms, and evidence of combining stimulants with other substances.
Critically, the evidence strongly indicates that treating ADHD reduces rather than increases substance use disorder risk. A large Swedish national registry study of nearly 39,000 people with ADHD (Chang et al., 2014) found no increased SUD risk with stimulant treatment, with substance-abuse rates about 31% lower among those prescribed medication and a long-term protective effect—longer treatment duration correlated with lower substance abuse rates. A meta-analysis showed treatment in childhood produced a 50% reduction in later drug and alcohol abuse. The explanation: untreated ADHD creates vulnerability (50% of adults with untreated ADHD will develop SUD), while appropriate treatment removes that vulnerability.
Special Populations Require Tailored Approaches
Adolescents show similar 70-80% response rates to stimulants as other age groups, but with unique considerations. Interestingly, after initial dose increases during growth, adolescents often need less medication after ages 15-16, possibly due to maturing metabolism and naturally waning symptoms. The greater concern is peer solicitation — more than half of adolescents who misuse prescription stimulants obtain them from friends or relatives. Transition to adult care represents a critical vulnerability, with research describing it as “poorly planned, poorly executed, and poorly experienced”; preparation should begin in early adolescence.
Adults diagnosed later in life often carry accumulated functional impairments from years of unrecognized symptoms, with higher rates of comorbid depression, anxiety, and relationship difficulties. They may have developed compensatory strategies or self-medicated with caffeine or nicotine. Over 80% respond favorably to stimulants but may require different dosing approaches based on body weight and metabolism.
During pregnancy and lactation, current guidelines from the American Journal of Obstetrics and Gynecology (2024) recommend psychoeducation and behavioral strategies for mild-moderate ADHD, with medication consideration at the lowest effective dose for moderate-severe cases. The consensus is that “the magnitude of documented risks is very low and that treatment with medications should not be stopped if they are required for daily functioning.” A 2024 JAMA Psychiatry study of 4.3 million pregnancies found ADHD medications were not associated with increased neurodevelopmental disorder risk in children after controlling for confounders. Methylphenidate is preferred over amphetamines if breastfeeding is planned due to lower transfer into breast milk.
Comorbid anxiety appears in 25-50% of children and up to 90% of adults with ADHD. Despite common concerns, stimulant medications demonstrate good tolerability and response in addressing symptoms—a 10-year longitudinal study found treated patients had lower incidence of secondary anxiety and depression. Guidelines recommend treating the more impairing condition first; often, addressing ADHD alleviates anxiety that stems from ADHD-related functional impairments. When stimulants worsen anxiety despite ADHD improvement, atomoxetine provides a first-line non-stimulant alternative with demonstrated benefits for both conditions.
Bipolar spectrum patients require careful management: without a mood stabilizer, methylphenidate increases mania risk 6-7 fold. However, with adequate mood stabilization first, Swedish registry data found “no evidence for a positive association between methylphenidate and treatment-emergent mania.” The clinical approach: stabilize bipolar disorder first, reassess for residual ADHD symptoms, then cautiously add stimulants with close monitoring.
Communicating Effectively with Patients About Tolerance
Patient education materials should target a 5th-8th grade reading level — the average US adult reads at 7th-8th grade level, and studies show most medical materials are written at an 11th-13th grade level, far above what most patients can understand. The Joint Commission recommends materials at or below 5th grade level.
The core messages patients need are straightforward:
“The goal is function, not feeling.” If tasks are getting completed, time is being managed, and relationships have improved, the medication is working—even if the subjective experience has changed.
“The honeymoon ends, and that’s normal.” The initial clarity or energy often fades within weeks; this doesn’t indicate tolerance but rather adjustment to life without the ADHD burden.
“Track what you can do, not how you feel.” A simple log of completed tasks, met deadlines, and kept commitments provides more useful information than subjective “focus” ratings.
“Needing adjustments isn’t failure.” Children need higher doses as they grow; adults may stabilize or even need less over time. The dose that works changes—this is normal pharmacology, not tolerance.
“Many factors affect how medication works.” Sleep, diet, stress, hormones, other medications, and comorbid conditions all influence apparent medication effectiveness. These should be evaluated before concluding tolerance has developed.
Frequently Asked Questions
Do ADHD medications really stop working over time?
For most people, no. True pharmacological tolerance — where the same dose genuinely does less — is uncommon, affecting somewhere between about 3% and 25% of patients depending on how it is measured. Far more often, what feels like a medication “quitting” traces to something else entirely: poor sleep, low iron, stress, hormonal shifts, or an untreated condition like anxiety or depression. Those are usually fixable.
Why did my medication feel amazing at first and then just “normal”?
That early lift — the unusual sense of clarity, energy, or calm in the first days or weeks — almost always fades, and that fading is normal. It reflects your brain settling in, not the medication failing. That first feeling was never the goal; steady, day-to-day functioning is. If you are still finishing tasks, keeping appointments, and getting along better with people, the medication is doing its job even though it no longer “feels” like much.
What should I check before assuming my medication stopped working?
Sleep first — stimulants work partly by mimicking a well-rested brain (Cell, 2025), so short or poor sleep blunts them. Also worth reviewing with your prescriber: iron (ferritin) levels, thyroid function, untreated anxiety or depression, and your timing around vitamin C and acidic drinks, which can reduce absorption of some amphetamines (though not Vyvanse). Sorting through these usually explains the change.
Should I just take a higher dose?
Not automatically. For many people, pushing the dose past a moderate level adds very little benefit while increasing side effects (Farhat et al., 2024). If a medication helps but wears off too soon, switching to a longer-acting version is often the better fix. If it never worked well, switching to a different class can help — roughly 40% of people respond better to one stimulant family than the other. These are conversations to have with your prescriber rather than changes to make on your own.
Are “medication holidays” a good idea?
Sometimes, but they are individual decisions. Planned breaks — over a summer, for instance — are common and may even give the body a reset. But breaks risk symptoms returning, and non-stimulant medications such as atomoxetine, guanfacine, and clonidine should never be stopped abruptly. Always plan any break with your prescriber rather than stopping on your own.
Does taking ADHD medication lead to addiction?
The evidence points the opposite way. A large Swedish national study of nearly 39,000 people with ADHD found that those treated had about 31% lower rates of substance abuse, with longer treatment linked to lower risk still (Chang et al., 2014). Untreated ADHD is itself a risk factor for substance problems; appropriate treatment appears to reduce that risk, not raise it.
How do I actually know if my medication is working?
Track what you do, not only how you feel. Are you completing tasks, meeting deadlines, keeping commitments, having fewer conflicts at home or work? Those real-world results matter more than a moment-to-moment “focus” sensation. If your functioning has improved and stayed improved, the medication is working — even if the early spark is gone.
Conclusion
The evidence paints a more optimistic picture than the common narrative of inevitable medication failure. True pharmacological tolerance affects a minority of patients (likely closer to the 2.7% long-term estimate than the 24.7% short-term figure), while the majority of cases where medication “stops working” trace to identifiable and addressable causes: sleep deprivation, nutritional deficiencies, comorbid conditions, hormonal fluctuations, or the normal fading of initial euphoric effects that were never the therapeutic goal.
The 2024-2025 research fundamentally reframes how we understand stimulant mechanisms—they enhance arousal and reward processing rather than attention directly, which explains both their effectiveness in sleep-deprived individuals and why subjective experiences change while functional benefits persist. Management strategies should progress through formulation switching, class switching, and non-stimulant alternatives rather than reflexive dose escalation, which shows diminishing returns. Perhaps most importantly, patient education must emphasize the distinction between feeling different (normal) and functioning worse (the actual signal of treatment failure), empowering patients to track meaningful outcomes while avoiding the pursuit of a subjective state that was never the medication’s purpose.
If you or someone you know is in crisis
- Call 911 or go to your nearest emergency room for any life-threatening emergency.
- 988 Suicide & Crisis Lifeline — call or text 988, available 24/7. En español: marque 988 y oprima 2. Veterans: 988 y oprima 1, or text 838255.
- Crisis Text Line — text HOME to 741741.
- The Trevor Project (crisis support for LGBTQ+ young people) — call 1-866-488-7386, or text START to 678-678.
- Riverside County — 24/7 crisis line 951-686-HELP (4357); CARES line 800-499-3008.
- San Bernardino County — DBH Screening/Referral 800-968-2636; DBH ACCESS 888-743-1478 (24/7); Mobile Crisis/CCRT 800-398-0018; crisis text 909-420-0560. Arrowhead Regional Medical Center (ARMC) has a dedicated adolescent psychiatric ER (ages 13–17).
- NP Fady (non-emergency) — for routine scheduling or questions, call (909) 707-6261. This line is not monitored for emergencies.